Transcat to Participate in the Northland Growth Conference 2025
Transcat Chief Executive Officer Lee Rudow and Chief Financial Officer Thomas Barbato will conduct one-on-one and small group meetings throughout the conference.
Northland Growth Conference 2025
Location: Virtual
Format: Virtual 1x1 and Small Group Investor Meetings
Attendees: Lee Rudow, Chief Executive Officer, Thomas Barbato, Chief Financial Officer, and Mike West, Chief Operating Officer
For more information on the conference, or to schedule a one-on-one meeting with Transcat management, please contact your Northland Capital Markets representative or you may also email your request to TRNS@mzgroup.us or call Chris Tyson at (949) 491-8235.
About Transcat
Transcat, Inc. is a leading provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing best-in-class services and products to highly regulated industries, particularly the Life Science industry, which includes pharmaceutical, biotechnology, medical device, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. Transcat provides periodic on-site services, mobile calibration services, pickup and delivery, in-house services at its 33 Calibration Service Centers strategically located across the United States, Puerto Rico, Canada, and Ireland. Inclusive of customer embedded locations and other field offices, we operate out of more than 50 locations. The breadth and depth of measurement parameters addressed by Transcat's ISO/IEC 17025 scopes of accreditation are believed to be the best in the industry.
Transcat also operates as a leading value-added distributor that markets, sells, and rents new and used national and proprietary brand instruments to customers primarily in North America. The Company believes its combined Service and Distribution segment offerings, experience, technical expertise, and integrity creates a unique and compelling value proposition for its customers.
Transcat's strategy is to leverage its strong brand and unique value proposition that includes its comprehensive instrument service capabilities, enterprise asset management, and leading distribution platform to drive organic sales growth. The Company will also look to expand its addressable calibration market through acquisitions and capability investments to further realize the inherent leverage of its business model. More information about Transcat can be found at: Transcat.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
25 minutes ago
- Business Insider
Meta Platforms (META) was downgraded to a Hold Rating at Freedom Capital Markets
Meta Platforms received a Hold rating and an $800.00 price target from Freedom Capital Markets analyst Saken Ismailov today. The company's shares opened today at $776.45. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Ismailov is ranked #7654 out of 9859 analysts. In addition to Freedom Capital Markets, Meta Platforms also received a Hold from BMO Capital's Brian Pitz in a report issued on July 31. However, today, Loop Capital Markets reiterated a Buy rating on Meta Platforms (NASDAQ: META). Based on Meta Platforms' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $47.52 billion and a net profit of $18.34 billion. In comparison, last year the company earned a revenue of $39.07 billion and had a net profit of $13.47 billion Based on the recent corporate insider activity of 287 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of META in relation to earlier this year. Most recently, in May 2025, SUSAN J LI, the CFO of META bought 13,859.00 shares for a total of $8,923,532.92.
Yahoo
44 minutes ago
- Yahoo
Amalgamated Financial (AMAL) Stock Trades Down, Here Is Why
What Happened? Shares of socially responsible bank Amalgamated Financial (NASDAQ:AMAL) fell 5.8% in the afternoon session after an analyst at Piper Sandler downgraded the stock to 'Underweight' from 'Neutral,' citing potential political and regulatory pressures. The investment firm also slashed its price target to $27 from $34. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Amalgamated Financial? Access our full analysis report here, it's free. What Is The Market Telling Us Amalgamated Financial's shares are not very volatile and have only had 6 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. Amalgamated Financial is down 17.2% since the beginning of the year, and at $27.47 per share, it is trading 28% below its 52-week high of $38.13 from November 2024. Investors who bought $1,000 worth of Amalgamated Financial's shares 5 years ago would now be looking at an investment worth $2,370. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
Yahoo
44 minutes ago
- Yahoo
Medical device industry says future MDUFA hikes unsustainable
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medical device companies advocated against future increases to user fees at a public hearing Monday for the next medical device user fee amendments. Meanwhile, Food and Drug Administration leaders, facing congressional budget cuts, made a case for more user fees, emphasizing the importance of the program. The five-year agreement determines the amount the FDA can raise from the medtech industry to supplement congressional appropriations. In the current MDUFA program, which ends in September 2027, the FDA's device center negotiated a boost in user fee funding in exchange for meeting certain review timelines and staffing levels. The next agreement would take effect in October 2027 and run through 2032. Michelle Tarver, director of the FDA's Center for Devices and Radiological Health, said the FDA 'requires sustained and increased investment by the medical device industry' to meet its goals. The device leader added that 'holding steady does not lead to excellence — it leads to mediocrity.' However, device industry lobbyists at the meeting indicated a preference for few changes. 'Each MDUFA cycle included significant resources and investments, including increasing the number of [full-time employees] to support the program,' said Janet Trunzo, senior executive vice president of technology and regulatory affairs for AdvaMed. 'Now that we have approached nearly 25 years … of user fee programs for medical devices, we are now in a position of merely fine-tuning the current program.' Mark Leahey, CEO of the Medical Device Manufacturers Association, called for the process to return 'back to the basics' in comments on Monday. Leahey said the funds from MDUFA should go to reviewers and medical officers, and added that the industry wants more visibility as to where the funds are going and 'where people are right now, realizing there's been some attrition over the last six months.' Citing the latest user fee rates, Leahey said more than $427 million in fees were authorized for fiscal year 2026. 'We have to realize the size and scope of the investments here,' he said. 'And this is not a sustainable pathway.' The meeting kicked off a process where the FDA will seek public comment through Sept. 4, before beginning negotiations with industry. When a final agreement is reached, the FDA will present it to Congress, which must approve the next MDUFA program. The negotiations come during a period of uncertainty, where several leaders have left the FDA under Health and Human Services Secretary Robert F. Kennedy Jr. The Trump administration's slashing of probationary FDA employees in February — followed by rehiring some staffers, and then more firings in April — raised questions about whether the FDA's user fees programs could be at risk. FDA Commissioner Marty Makary has suggested lowering user fees for prescription drugs; however, he has not indicated any major changes to medical device fees, referring to MDUFA as 'the best of all the user fee arrangements' during the meeting. Patient advocates call for more fees, transparency While industry pushed back against further fee increases, patient groups called for more fees to offset federal budget cuts to the FDA. Diana Zuckerman, president of the National Center for Health Research, said that given recent cuts in FDA staffing and the importance of speedy device reviews, 'it's inevitable that improving quality requires increasing the fees.' Zuckerman said that while she would like to see Congress provide enough appropriations for the FDA's device center, 'we want to make sure that there's funding for everything that's needed, and, unfortunately, appropriations isn't making that possible.' Zuckerman also called for user fees to be used for postmarket device safety, as well as for more transparency during the negotiation process, positions that were supported by other patient advocates during the meeting. In the past, user fee negotiations have been behind closed doors, and patients, consumers and health professionals have not been able to join or observe the meetings, Zuckerman said. In the last round of negotiations, the FDA also faced scrutiny for not publishing meeting minutes from its conversations with industry in a timely fashion. 'At the very least, we should have access to remotely watch those negotiations, instead of just depending on minutes that are often vague or very delayed so that stakeholders have no opportunity for meaningful input,' said Tess Robertson-Neel, on behalf of the Patient, Consumer, & Public Health Coalition, a group of more than two dozen nonprofits. Robertson-Neel added that user fees should be increased, and the FDA should focus on being 'more patient-centered and transparent and less cozy with industry.' Alexander Naum, policy manager for Generation Patient, a nonprofit representing young adults living with chronic medical conditions, said that user fees must increase and the next MDUFA agreement should include clear postmarket device safety performance goals. He also asked for the FDA to commit funds to expanding its program for tracking medical device adverse events. Naum cited a statistic that the FDA receives more than 2 million reports annually of suspected device malfunctions, serious injuries or deaths. 'So many of us rely on medical devices for our survival,' Naum said. 'Many of these devices present the potential of unexpected adverse events.' Recommended Reading FDA schedules first public MDUFA VI meeting ahead of negotiations Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
